论文部分内容阅读
本刊讯免疫治疗作为新兴肿瘤治疗方法越来越受关注,《科学》杂志将其列为2013年度十大科技进展之首。但也不是每个人都有效。因此,如何预测哪些类型肿瘤患者对于免疫治疗有效,正是该领域的前沿问题。近日出版的一期《癌细胞》杂志,以封面论文的形式发表了中国工程院院士、医学免疫学国家重点实验室主任曹雪涛研究团队肿瘤免疫治疗转化的研究成果,揭示了通过维甲酸诱导基因I(RIG-I)表达水平高低,可以预测肝癌患者对于接受干扰素治疗是否有效。我国是世界上肝癌患者最多的国家,对于晚期肝癌患者目前尚缺乏有效的治疗手段。临床观察发现,仅有部分肝癌患
As a new cancer treatment method, immunotherapy has attracted more and more attention, and Science magazine ranked it as the top ten scientific and technological progress in 2013. But not everyone is effective. Therefore, how to predict which types of cancer patients are effective for immunotherapy is the frontier issue in this field. Recently published a “cancer cell” magazine, published in the form of a cover paper academician of Chinese Academy of Engineering, State Key Laboratory of Medical Immunology Cao Xuedao research team tumor immunotherapy transformation research results reveal that through the retinoic acid induced gene I ( RIG-I) expression level, can predict whether the liver cancer patients for interferon treatment is effective. China is the country with the largest number of liver cancer patients in the world, and there is still no effective treatment for patients with advanced liver cancer. Clinical observation found that only part of liver cancer